Afatinib

Anti-angiogenesis

MECHANISM OF ACTION

EGFR-I

MECHANISM OF KIDNEY INJURY

Selective TKI that binds to EGFR

CLINICAL KIDNEY SYNDROME

extra-renal, Decrease EF, GI toxicity, Hepatic toxicity, cystitis, ILD
Unclear direct impact on Kidney

CARDIOVASCULAR ADVERSE EFFECTS

cardiomypathy, decreased in LV ejection fraction

LYTE ABNORMALITIES

hypomagnesemia

RISK FACTORS

Unclear

MITIGATION STRATEGIES

Unclear

SUGGESTIONS

NOTES/COMMENTS

eGFR < 60 ml/min, no dose adjustment
eGFR < 30 ml/min, 30 mg/day

PHARMACOKINETICS

Molecular Weight

Volume of Distribution

Plasma Protein Binding

95%

Metabolism

Bioavailability

Half-life elimination

37 hours

Time to peak

Excretion

Feces 85%

Dialyzable?

Unclear, no dose adjustment recommended on HD.

REF:

PATHOLOGY SLIDES:

ENTRY UPDATES:

Raad Chowdhury

United States

Sep 25, 2022

PARTNERS WITH